Wright T C, Denny L, Kuhn L, Pollack A, Lorincz A
Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
JAMA. 2000 Jan 5;283(1):81-6. doi: 10.1001/jama.283.1.81.
More than half of the women diagnosed as having cervical cancer in the United States have not been screened within the last 3 years, despite many having had contact with the health care system. In many other regions of the world, there is only limited access to cervical cancer screening.
To determine whether testing of self-collected vaginal swabs for human papillomavirus (HPV) DNA can be used to screen for cervical disease in women aged 35 years and older.
Cross-sectional observational study comparing Papanicolaou smears with HPV DNA testing of self-collected vaginal swabs.
Outpatient clinics in a periurban settlement outside of Cape Town, South Africa, between January 1998 and April 1999.
Screening was performed on 1415 previously unscreened black South African women aged 35 to 65 years.
Women self-collected a vaginal swab for HPV testing in the clinic and were then screened using 4 different tests: Papanicolaou smear, direct visual inspection of the cervix after the application of 5% acetic acid, cervicography, and HPV DNA testing of a clinician-obtained cervical sample. Women with abnormal results on any of the screening tests were referred for colposcopy.
Biopsy-confirmed high-grade cervical squamous intraepithelial lesions or invasive cancer.
High-grade squamous intraepithelial lesions were identified in 47 (3.4%) of 1365 women adequately assessed, and there were 9 cases of invasive cancer. Of women with high-grade disease, 66.1% (95% confidence interval [CI], 52.1%-77.8%) had high risk for HPV detected in self-collected vaginal samples, and 67.9% (95% CI, 53.9%-79.4%) had an abnormal Papanicolaou smear (P = .78). The false-positive rates for HPV DNA testing of self-collected vaginal samples and Papanicolaou smears were 17.1% (95% CI, 15.1%-19.3%) and 12.3% (95% CI, 10.5%-14.2%), respectively (P<.001). A high-risk type of HPV DNA was detected in 83.9% (95% CI, 71.2%-91.9%) of women with high-grade disease and 15.5% (95% CI, 13.6%-17.7%) of women with no evidence of cervical disease using a clinician-obtained cervical sample.
These results indicate that HPV testing of self-collected vaginal swabs is less specific than but as sensitive as Papanicolaou smears for detecting high-grade cervical disease in women aged 35 years and older, and HPV testing offers an important new way to increase screening in settings where cytology is not readily performed.
在美国,超过半数被诊断为宫颈癌的女性在过去3年内未接受过筛查,尽管她们中的许多人曾与医疗保健系统有过接触。在世界其他许多地区,宫颈癌筛查的可及性也很有限。
确定对自行采集的阴道拭子进行人乳头瘤病毒(HPV)DNA检测是否可用于筛查35岁及以上女性的宫颈疾病。
将巴氏涂片与自行采集的阴道拭子HPV DNA检测进行比较的横断面观察性研究。
1998年1月至1999年4月期间,南非开普敦市郊一个定居点的门诊诊所。
对1415名年龄在35至65岁、此前未接受过筛查的南非黑人女性进行筛查。
女性在诊所自行采集阴道拭子进行HPV检测,然后使用4种不同检测方法进行筛查:巴氏涂片、涂抹5%醋酸后直接目视检查宫颈、宫颈造影以及对临床医生采集的宫颈样本进行HPV DNA检测。任何一项筛查检测结果异常的女性均被转诊接受阴道镜检查。
活检确诊的高级别宫颈鳞状上皮内病变或浸润癌。
在1365名接受充分评估的女性中,有47名(3.4%)被确诊为高级别鳞状上皮内病变,有9例浸润癌。在患有高级别疾病的女性中,66.1%(95%置信区间[CI],52.1%-77.8%)在自行采集的阴道样本中检测到高危型HPV,67.9%(95%CI,53.9%-79.4%)巴氏涂片结果异常(P = 0.78)。自行采集的阴道样本HPV DNA检测和巴氏涂片的假阳性率分别为17.1%(95%CI, 15.1%-19.3%)和12.3%(95%CI, 10.5%-14.2%)(P<0.001)。使用临床医生采集的宫颈样本,83.9%(95%CI, 71.2%-91.9%)患有高级别疾病的女性和15.5%(95%CI, 13.6%-17.7%)无宫颈疾病证据的女性检测到高危型HPV DNA。
这些结果表明,对于检测35岁及以上女性的高级别宫颈疾病,自行采集阴道拭子进行HPV检测的特异性低于巴氏涂片,但敏感性与之相当,并且HPV检测为在不易进行细胞学检查的环境中增加筛查提供了一种重要的新方法。